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Current global concerns
In the 2015 State of the World’s Antibiotics[1] report, an increasing 
incidence of extensively drug-resistant Gram-negative bacteria 
was highlighted for South Africa (SA), underscoring SA’s 
increasing reliance on colistin as a last line of defence. Although 
colistin resistance was first reported in the Czech Republic in 1999 
and was subsequently only reported sporadically, recent reports 
of increasing colistin resistance among clinical isolates, including 
from SA, are cause for alarm.[2,3] Of particular concern is the 
emergence of colistin resistance among commonly encountered 
Enterobacteriaceae such as Klebsiella pneumoniae. Up to now, the 
mechanism of colistin resistance in SA isolates was due to changes 
in genes associated with complex alterations in the bacterial 
regulatory systems.[4] These genes were not readily transferrable 
between species.
Recent routine surveillance of antibiotic resistance in commen-
sal Escherichia coli from food animals in China documented a major 
increase of colistin resistance due to a highly mobile, transferrable, 
plasmid-mediated colistin-resistance gene designated mcr-1.[5] 
They observed mcr-1 in E. coli isolates collected from 15% 
(78/523) of raw retail meat samples (chicken and pork) and 21% 
(166/804) of animals (pigs) during 2011 - 2014. Of note, 1% 
(16/1 322) of clinical isolates from infected, hospitalised Chinese 
patients harboured mcr-1. The authors demonstrated trans fer of 
mcr-1 between E. coli strains, including strains with known epi-
demic potential, such as ST131. Furthermore, the plasmid could 
be passed to K. pneumoniae and even Pseudomonas aeruginosa 
strains. 
Globally, the dissemination of mcr-1 among E. coli strains from 
feed animals and asymptomatic humans has now been reported 
from at least 17 countries. Recently, Dutch travellers to Asia 
(China, Thailand, Vietnam, Cambodia and Laos), North Africa 
(Tunisia) and South America (Peru, Bolivia and Colombia) were 
reported, after their travels, to have gastrointestinal colonisation 
with mcr-1-containing E. coli.[6] mcr-1 has also been detected 
among Salmonella spp. collected in 2012 - 2013 from the French 
agricultural food sector and has been confirmed in Salmonella 
enterica serotype typhimurium cultured from food samples in 
Portugal. In addition, the mcr-1 gene has been identified in clinical 
isolates of K.  pneumoniae and in association with carbapenemase 
genes.[7] 
Current situation in SA
A countrywide surveillance programme of poultry operations 
revealed that colistin resistance in E. coli strains increased 
substantially in 2015, predominantly in the second half of the year. [8] 
It was surmised that this sudden increase was likely due to the 
selection of mcr-1-containing strains where colistin was being used. 
Subsequent analysis detected mcr-1 in 19/24 (79%) colistin-resistant 
cultures from the last quarter of 2015. 
Of critical importance, mcr-1 has now been detected in 
clinical isolates of colistin-resistant E. coli from hospitalised 
(n=3) and outpatient-based (n=6) patients in SA. This has 
been con firmed by a specialised antibiotic resistance unit in 
Switzerland that performed confirmatory molecular studies 
including plasmid characterisation (submitted for publication). 
As depicted in Table  1, mcr-1-positive, colistin-resistant E. coli 
was cultured from patients in two SA provinces. Except for 
one patient with an abscess, all the community-acquired cases 
presented to primary care with urinary tract infections. None 
was previously exposed to colistin. mcr-1 leads to raised colistin 
minimum inhibitory concentrations of 4 - 8 mg/L. Four of the 
isolates coproduced an extended-spectrum β-lactamase (data 
not shown).
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The polymyxin antibiotic colistin is an antibiotic of last resort for the treatment of extensively drug-resistant Gram-negative bacteria, 
including carbapenemase-producing Enterobacteriaceae. The State of the World’s Antibiotics report in 2015 highlighted South Africa (SA)’s 
increasing incidence of these ‘superbugs’ (3.2% of Klebsiella pneumoniae reported from SA were carbapenemase producers), and in doing 
so, underscored SA’s increasing reliance on colistin as a last line of defence. Colistin resistance effectively renders such increasingly common 
infections untreatable.
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Implications for public health
The national and global significance of the sudden spread of 
MCR-1 and the attendant loss of colistin has profound public health 
implications, and confirms the continuum between colistin use in 
feed animals and colistin resistance in slaughtered animals, food 
for human consumption, colonised humans and infected patients. 
We join the international community in calling for tighter control 
of colistin use in animal health, including a ban on use for animal 
growth promotion and the need for an urgent review of its use in 
metaphylaxis in feed animals and directed therapy in companion 
animals. We also call for increased restriction of colistin use in 
patients. In this regard, redefined considerations for empirical and 
directed use of colistin are urgently warranted. Strict antibiotic 
stewardship is essential, including a mandatory loading dose of 12 
million units, and use only in combination with at least one other 
agent. 
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Table 1. Demographics of clinical isolates of mcr-1-containing E. coli 
Age (years), 
sex Source
Admission 
date Culture date
Colistin
MIC (mg/L)
Clinical 
diagnosis
Prior 
colistin City
Additional 
comments
1 54, M Blood NR 23 March 2014 4 Stem cell 
transplant
No Pretoria Prior carbapenem 
and fluoroquinolone 
treatment
2 60, F Wound
(bedsore)
9 February 
2015 (ICU)
12 March 2015 4 AIDS, TB, 
P. jirovecii 
pneumonia
No Johannesburg On antiretrovirals, 
TB and P. jirovecii 
treatment
3 73, F Urine 17 November 
2015 (ward)
21 November 
2015
4 UTI No Johannesburg Admitted for hip 
replacement
4* 48, F Pus Outpatient 23 March 2014 4 Perianal abscess No Johannesburg No prior antibiotics
5* 60, F Urine Outpatient 7 October 2014 8 UTI No Johannesburg No prior antibiotics
6* 63, F Urine Outpatient 11 May 2015 8 UTI No Johannesburg Chronic UTIs. 
Previously treated
with nitrofurantoin 
and fosfomycin 
7* 68, F Urine 28 May 2015 28 May 2015 4 UTI No Johannesburg Admitted for hip 
replacement, diabetic
8* 36, F Urine Outpatient 29 May 2015 4 UTI No Pretoria Previous hospitali sation 
(>6 months) for renal 
transplant
 9* 19, F Urine Outpatient 24 January 2016 4 UTI No Cape Town No prior antibiotics
M = male; F =  female; NR = not recorded; PCR = polymerase chain reaction; ICU = intensive care unit; MIC = minimum inhibitory concentration; TB = tuberculosis; UTIs = urinary tract infections.
*Outpatient managed by primary care physician.
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